Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.
- Published In:
- Frontiers in pharmacology, 14, 1226778 (2023)
- Authors:
- Feng, Zhen, Tong, Wai Kei, Zhang, Xinyue, Tang, Zhijia
- Database ID:
- RPEP-06871
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06871APA
Feng, Zhen; Tong, Wai Kei; Zhang, Xinyue; Tang, Zhijia. (2023). Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.. Frontiers in pharmacology, 14, 1226778. https://doi.org/10.3389/fphar.2023.1226778
MLA
Feng, Zhen, et al. "Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.." Frontiers in pharmacology, 2023. https://doi.org/10.3389/fphar.2023.1226778
RethinkPeptides
RethinkPeptides Research Database. "Cost-effectiveness analysis of once-daily oral semaglutide v..." RPEP-06871. Retrieved from https://rethinkpeptides.com/research/feng-2023-costeffectiveness-analysis-of-oncedaily
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.